Brief: Lipocine Reports Topline Safety & Efficacy Results For LPCN 1154 In Patients With Postpartum Depression
02/04/2026 13:14
April 2 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE REPORTS TOPLINE SAFETY AND EFFICACY RESULTS FOR LPCN 1154 IN PATIENTS WITH POSTPARTUM DEPRESSION LIPOCINE INC - LPCN 1154 PHASE 3 PRIMARY ENDPOINT NOT MET IN PPD PATIENTS LIPOCINE INC - LPCN 1154 SHOWS STATISTICALLY SIGNIFICANT HAM-D REDUCTIONS IN PSYCHIATRIC HISTORY SUBSET LIPOCINE INC - NO SEVERE ADVERSE EVENTS OR DISCONTINUATIONS REPORTED FOR LPCN 1154 LIPOCINE INC - LPCN 1154 WELL TOLERATED WITH NO ADVERSE EVENT IN OVER 5% OF PARTICIPANTS Source text: ID:nPnn5JyCa Further company coverage: LPCN.O
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy